Mysimba 8 mg/90 mg

Mysimba 8mg/90mg
Mysimba 8mg/90mg is an oral medication used to help obese adults lose and maintain weight. This drug acts on areas of the brain involved in the regulation of food intake and energy consumption. Mysimba contains bupropion. Bupropion is indicated for the treatment of depression in some countries. A meta-analysis of placebo-controlled clinical trials of antidepressants in adult subjects with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in subjects less than 25 years old.
Mysimba may be discontinued by your doctor after 16 weeks if you have not lost at least 5 percent of your initial body weight. Your doctor may also recommend stopping treatment if there are concerns. Naltrexone and bupropion are the substance names of the drug used in Mysimba. One controlled-release tablet contains 8 mg of naltrexone(hydrochloride) and 90 mg of bupropion(hydrochloride). Naltrexone reduces food cravings and bupropion acts on the reward system in the brain to reduce appetite.
Mysimba is a prescription drug, meaning it is available only with a doctor’s prescription. Mysimba is particularly effective when used in conjunction with a lifestyle plan. Although in placebo-controlled clinical trials with naltrexone/bupropion for the treatment of obesity in adult subjects, no suicides or suicide attempts were reported in studies up to 56 weeks duration with naltrexone/bupropion, suicidality events (including suicidal ideation) have been reported in subjects of all ages treated with naltrexone/bupropion post-marketing.
The drug Mysimba may be reimbursed from the basic package for the treatment of a small group of overweight people. Reimbursement applies only to people with a Body Mass Index (BMI) of 30 or higher, or 27 or higher with a weight-related condition, who have been participating in the combined lifestyle intervention (GLI) for at least 1 year and have not achieved sufficient weight loss as a result.